<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Nakamura, Kunio</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">BRAVO Analysis: Laquinimod Reduces Brain Atrophy in Patients with RRMS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-9</style></pages><abstract><style  face="normal" font="default" size="100%">Laquinimod, an oral immunomodulator under development for the treatment of multiple sclerosis (MS), reduced whole brain atrophy in the ALLEGRO and BRAVO trials [Vollmer T et al. Neurology. 2012]. This study analyzed the effect of laquinimod on the percent volume change in gray and white matter in the phase 3 BRAVO trial [Vollmer T et al. J Neurol. 2014], using a newly developed, longitudinal image analysis technique.</style></abstract><number><style face="normal" font="default" size="100%">29</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>